Maria Galang-Qahwash, DO
Ophthalmology · Owosso, MINPI 1952594079
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (48.6%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 59.3% of the total. Reporting peaked in 2019 at $3,528 and has fallen 91.7% since, to $292 in 2025.
Across 94 payments — averaging $52.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$3K
- AbbVie$294
- Ocular Therapeutix, Inc.$189
- Bausch & Lomb, A Division Of Bausch Health US, LLC$179
- Carl Zeiss Meditec, Inc.$178
- Alcon$177
- plus $978 from 17 others
What the payments were for
- Consulting fees$1,13223%
- Travel & lodging$1,34727%
- Food & beverage$2,38349%
- Education$50%
- Gifts$391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 6 | $2,912 |
| AbbVie(2 entities) | 12 | $294 |
| Ocular Therapeutix, Inc. | 10 | $189 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $179 |
| Carl Zeiss Meditec, Inc. | 2 | $178 |
| Alcon | 8 | $177 |
| Bausch & Lomb Americas Inc. | 3 | $137 |
| Biotissue Holdings Inc. | 6 | $109 |
| Tarsus Pharmaceuticals, Inc. | 4 | $108 |
| Novartis | 5 | $89 |
| Mallinckrodt Enterprises LLC | 4 | $89 |
| Kala Pharmaceuticals, Inc. | 5 | $88 |
| Amgen(2 entities) | 2 | $55 |
| Mallinckrodt Hospital Products Inc. | 3 | $53 |
| Sun Pharmaceutical Industries Inc. | 3 | $49 |
| Dompe US, Inc. | 2 | $44 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Harrow Eye, LLC | 1 | $32 |
| Shire North American Group Inc | 2 | $25 |
| Sight Sciences, Inc. | 1 | $19 |
| NEW World Medical,inc. | 1 | $16 |
| Rayner Intraocular Lenses Limited | 1 | $15 |
| Omeros Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Premium Cataract IOLs$1,780
- Tecnis Symfony IOL$1,132
- VisuMax$123
- ARTEVO 800$123
- DURYSTA$111
- MIEBO$104
- XIIDRA$104
How this compares
$4,907 in reported general payments places this provider in the 85th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 32 | $40,364 |
| CequaCyclosporine | 23 | $23,349 |
| Cyclosporine | 34 | $21,275 |
| RestasisCyclosporine | 17 | $12,964 |
| LumiganBimatoprost | 15 | $5,047 |
| TafluprostTafluprost/Pf | 13 | $2,391 |
| Ofloxacin | 157 | $1,789 |
| Brinzolamide | 14 | $1,769 |
| Ketorolac Tromethamine | 34 | $1,565 |
| Timolol Maleate | 50 | $1,349 |
| Latanoprost | 76 | $1,270 |
| ValacyclovirValacyclovir Hcl | 16 | $872 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $594 |
| Brimonidine Tartrate | 51 | $490 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 34 | $483 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra | $137 | $40,36432 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $49 | $23,34923 claims |
| AbbVieRestasis, Lumigan | $294 | $18,01132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Owosso
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
- Yannis PaulusAnn Arbor$85K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.